文献速递骨软组织肉瘤与黑色素瘤

BayeSarc:贝叶斯序贯学习用于肢体软组织肉瘤预后预测

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.
PubMed 文献 · Lancet Oncol · 2026-01-01

这项回顾性多中心队列研究纳入4916例手术治疗的肢体软组织肉瘤成人患者,基于贝叶斯序贯学习开发可连续更新的BayeSarc模型。

要点

  • BayeSarc可连续纳入新队列更新,适应时间变化并优化变量权重。
  • 最终更新后总生存与远处转移的区分度均优于Sarculator。
  • 已整合入Sarculator应用,可即刻用于临床咨询与治疗决策。

核心结论

  • BayeSarc是可用于肢体软组织肉瘤的连续更新、准确且精确的预后工具,能降低不确定性并适应时间变化。

研究设计与样本

  • 回顾性多中心队列研究,纳入4916例成人原发性、局限、手术治疗的肢体软组织肉瘤患者,来自意大利、加拿大、法国、英国和美国的六个队列。
  • BayeSarc使用与Sarculator相同的临床病理变量(年龄、大小、分级和组织学),以意大利国家肿瘤研究所历史队列开发,并依次用五个独立队列更新。
  • 采用贝叶斯Cox模型(总生存)和Fine-Gray模型(远处转移粗累积发生率),在贝叶斯序贯学习框架内结合贝叶斯更新与先验信息自适应借用。

主要发现

  • 校准在各次更新中持续改善,估计与预测的不确定性降低。

临床怎么用

  • BayeSarc已整合入Sarculator应用,可即刻用于临床患者咨询、治疗决策和试验设计优化。
  • 贝叶斯序贯学习框架为罕见肿瘤预后研究提供了超越传统两步开发-验证范式的新方法。

局限性

  • 本研究为回顾性设计,证据等级受限于此。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarculator is a widely validated prognostic tool that estimates overall survival and crude cumulative incidence (CCI) of distant metastasis in patients with resected soft tissue sarcomas in the extremities. Sarculator relied on external cohorts only for performance testing and could not incorporate new information or adapt to temporal changes. We aimed to develop BayeSarc, a prognostic model based on Bayesian sequential learning (BSL), which enables continuous updating by incorporating new clinical cohorts and provides more accurate estimates. METHODS: In this retrospective, multicentre cohort study, eligible patients were adults (aged ≥18 years) with primary, localised, surgically treated soft tissue sarcomas in the extremities (excluding desmoid tumours, undifferentiated small round cell sarcoma of soft tissue, alveolar or embryonal rhabdomyosarcoma, dermatofibrosarcoma protuberans, and well differentiated liposarcoma). Data were retrieved from institutional databases at each participating hospital. BayeSarc used the same clinicopathological variables as Sarculator (age, size, grade, and histology) and was developed with a historical cohort of consecutive patients treated surgically at the Istituto Nazionale dei Tumori (Milan, Italy) and sequentially updated with five independent cohorts from Canada, France, the UK, USA, and Italy. Bayesian Cox (overall survival) and Fine-Gray (CCI distant metastasis) models were reformulated within a BSL framework combining Bayesian updating with prior-information adaptive borrowing. The primary objective was to compare the discrimination and calibration of BayeSarc versus Sarculator for predicting overall survival and CCI-distant metastasis. We evaluated the performance of BayeSarc at each update using prequential estimates, reflecting model transport to a new cohort without local recalibration, and post-update estimates, reflecting performance after sequential updating. FINDINGS: We included a total of 4916 patients (2204 [44·8%] female, 2694 [54·8%] male, and 18 [0·4%] with sex not recorded) drawn from six cohorts: Istituto Nazionale dei Tumori, Milan, Italy (Jan 1, 1994-Dec 31, 2013; median follow-up 86 months [IQR 81-90]); Mount Sinai Hospital, Toronto, Canada (Jan 1, 1994-Dec 31, 2013; 85 months [81-90]); Institut Gustave Roussy, Villejuif, France (Jan 1, 1996-May 15, 2012; 75 months [68-82]); Royal Marsden Hospital, London, UK (Jan 1, 2006-Dec 31, 2013; 54 months [48-59]); Brigham and Women's Hospital, Boston, USA (Jan 1, 2014-Dec 31, 2021; 72 months [66-84]); and Istituto Nazionale dei Tumori, Milan, Italy (Jan 1, 2014-Dec 31, 2021; 61 months [57-64]). 12 patients from the UK were missing follow-up data and were excluded from survival analyses. At the final step of the BSL update, BayeSarc achieved higher discrimination than Sarculator for both overall survival (prequential mean C index: 0·784 [95% credible interval 0·759-0·794]; after update: 0·801 [0·790-0·809]; Sarculator: 0·773) and distant metastasis (prequential mean C index: 0·723 [0·704-0·738]; after update: 0·738 [0·730-0·743]; Sarculator: 0·718). Calibration improved consistently across updates, and uncertainty around estimates and predictions decreased. INTERPRETATION: BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development-validation paradigm, enabling more efficient use of patient data. FUNDING: Associazione Italiana per la Ricerca sul Cancro, Cancer Research UK, Fundacion Científica, and Asociacion Espanola Contra el Cancer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Callegaro D, Tinè G, Pasquali S, et al. Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study. Lancet Oncol. 2026. PMID: 42061374. doi:10.1016/S1470-2045(26)00067-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。